Prodotti competitors / Area Kite
EMA validates Regeneron's linvoseltamab MAA in r/r MM
![Immagine News](/media/l4el5htd/cat-2.jpg?anchor=center&mode=crop&width=722&height=442)
Regeneron has announced that the EMA has validated its MAA for linvoseltamab for the treatment of adult patients with relapsed/refractory (r/r) multiple myeloma (MM) who have progressed after at least three prior therapies.
The MAA is supported by data from a Phase 1/2 pivotal trial (LINKER-MM1) investigating linvoseltamab in r/r MM. LINKER-MM1 is an open-label, multicenter Phase 1/2 dose-escalation and dose-expansion trial.
A Biologics License Application (BLA) was also submitted to the FDA in December 2023.
Reference link: Regeneron press release
Grazie per il tuo feedback!